Attachment 4 - ClinicalTrials.gov Results Reporting Data Entry Screen Shots

ClinicalTrials.gov PRS
Protocol Registration and Results System

Login

Welcome to the ClinicalTrials.gov Protocol Registration and Results System (PRS).

OMB NO: 0925-0586
EXPIRATION DATE: 08/31/2015
Burden Statement

Organization: [   ]
One-word organization name assigned by PRS (sent via email when account was created)

Username: [   ]

Password: [   ]   Forgot password

Login

See Submit Studies on ClinicalTrials.gov for information on how to apply for an account, how to register your study, and how to submit results.

Send email to ClinicalTrials.gov PRS Administration

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services

OMB NO: 0925-0586
EXPIRATION DATE: 08/31/2015
Burden Statement

Public reporting burden for this collection of information is estimated to average 7.0 hours per response for initial registration, 2.0 hours for each of 8 updates to the registration information during the course of the trial, 25.0 hours per response for initial results submission, 8.0 hours for two substantive updates to the results information. These estimates include the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0586). Do not return the completed form to this address

Home > Record Summary > Results Section > Participant Flow > Edit

| NLM | ID: jftest | Test Test Test Test Test Test | [NCT ID not yet assigned] |

Edit Participant Flow

Help   Definitions

| Recruitment Details: | Edit |
| Pre-assignment Details: | Edit |

Arms/Groups (2)   + Add Arm/Group

	Edit	Edit
* Arm/Group Title:	**wonderdrug**	**placebo**
Arm/Group Description:	test test test	test test test
	× Delete Move ▶	× Delete ◀ Move

Periods (1)   Protocol Enrollment: 200

* Period Title:	Overall Study		

	wonderdrug	**placebo**	Total 🗐 (Not public)
* Started:	[____] Add Comment	[____] Add Comment	unknown
+ Add Milestone			
* Completed:	[____] Add Comment	[____] Add Comment	unknown
Not Completed: (Started - Completed)	unknown	unknown	
Reason Not Completed			
-- Select Reason Type -- ▼ × Delete	[____]	[____]	unknown
+ Add Reason Not Completed	Not Completed = unknown Total from all reasons = unknown	Not Completed = unknown Total from all reasons = unknown	

+ Add Period

Save   Validate   Cancel

NLM   ID: jftest   Test Test Test Test Test Test   [NCT ID not yet assigned]

Edit Baseline Arm/Groups

+ Add Arm/Group   Help   Definitions

* Arm/Group Title:	wonderdrug	placebo
	Characters remaining: 985	Characters remaining: 985
Arm/Group Description:	test test test	test test test
	× Delete Move ▶	× Delete ◀ Move

Baseline Measures

Age, Continuous test 1		
Gender, Male/Female Female Male		
Region of Enrollment United States		

Save   Cancel

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services

NLM   ID: jftest   Test Test Test Test Test Test   [NCT ID not yet assigned]

Edit Baseline Analysis Population

Help   Definitions

	wonderdrug	placebo
* Overall Number of Baseline Participants:		

	Characters remaining: 350
Baseline Analysis Population Description:	

Save   Cancel

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services

NLM   ID: jftest   Test Test Test Test Test Test   [NCT ID not yet assigned]

Edit Baseline Measure

Help   Definitions

* Baseline Measure Title:	Age, Continuous
Baseline Measure Description:	[Edit] Additional information about the measure (e.g., description of scale)

	wonderdrug	placebo	Total
Overall Number of Baseline Participants:	---	---	---

* Measure Type:	Mean ▼		
* Measure of Dispersion:	Standard Deviation ▼		
* Category Title	**Mean** [ ]	**Mean** [ ]	**Mean** [ ]
test 1	**Standard Deviation** [ ]	**Standard Deviation** [ ]	**Standard Deviation** [ ]
+ Add Category			
* Unit of Measure:	years Commonly reported units: [years]		

[Save]   [Validate]   [Cancel]

NLM   ID: jftest   Test Test Test Test Test Test   [NCT ID not yet assigned]

Outcome Measure Data

Help   Definitions

* Outcome Measure Type:	Primary ▼
* Outcome Measure Title:	Characters remaining: 227 Test Outcome Measure Title 1
Outcome Measure Description:	Characters remaining: 999
* Outcome Measure Time Frame:	5 weeks
(‡) Safety Issue?	No ▼

Arms/Groups (1)   + Add Arm/Group

[Edit]

* Arm/Group Title:	**test**
Arm/Group Description:	test test test
* Number of Participants Analyzed:	100
Type of Units Analyzed [ ] × Delete	[ ]
Analysis Population Description:	Characters remaining: 350

Outcome Measure Data Table

* Measure Type:	Number ▼
* Measure of Dispersion/Precision:	Not Applicable ▼

	test
* Category Title Title 1 × Delete ▼ Move	**Number** 50
* Category Title Title 2 × Delete ▲ Move	**Number** 50
+ Add Category	
* Unit of Measure:	participants Commonly reported units: participants	years	units on a scale	percentage of <something>

Save Validate Cancel

* Required by ClinicalTrials.gov

‡ = FDAAA Required to comply with US FDA Amendments Act

(‡) = (FDAAA) May be required to comply with US FDA Amendments Act

| NLM | ID: jftest | Test Test Test Test Test Test | [NCT ID not yet assigned] |

Add Outcome Statistical Analysis

Primary Outcome	
Title:	test test test test test
Time Frame:	forever
Unit of Measure:	participants

Tip: Many of the data elements are optional and may be left blank. The minimum requirements are to enter either a P-Value OR an Estimation Parameter (e.g., Mean Difference, Odds Ratio). A Confidence Interval for the Estimation Parameter may also be entered.

Statistical Analysis Overview

Help   Definitions

* Comparison Group Selection: Select the Outcome Measure Arms/Groups involved in the statistical analysis.
☐ test

Comments: (Optional) Additional details about the statistical analysis, such as null hypothesis and description of power calculation.

Characters remaining: 500

* Non-inferiority or Equivalence Analysis? -- Please Select -- ▼

Comments: If "Yes" (non-inferiority or equivalence analysis), describe details of the power calculation (if not previously provided), definition of non-inferiority margin, and other key parameters.

Characters remaining: 500

Statistical Test of Hypothesis

Help   Definitions

P-Value: (If applicable)

_____ (e.g. <0.01)

Comments: (Optional) Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the *a priori* threshold for statistical significance.

Characters remaining: 250

Method: (Required if a P-Value is entered)

-- Please Select -- ▼   If other, please specify: _____

Comments: (Optional) Any other relevant information, such as adjustments or degrees of freedom.

Characters remaining: 150

Method of Estimation

Help   Definitions

Estimation Parameter: (If applicable)

-- Please Select --   If other, please specify: [   ]

Estimated Value: Provide the data for the Estimation Parameter.

[   ]

Confidence Interval: (If applicable) ⊘

[   ] % Confidence Interval

Number of sides [2-Sided ▾]
Lower Limit: [   ]
Upper Limit: [   ]

Parameter Dispersion Type   (If applicable)
and Dispersion Value:

-- Please Select --   [   ]

Estimation Comments: (Optional) Any other relevant estimation information, including the direction of the comparison (e.g., describe which arm or comparison group represents the numerator and denominator for relative risk).

Characters remaining: 250

[   ]

[Save] [Validate] [Cancel]

| NLM | ID: jftest | Test Test Test Test Test Test | [NCT ID not yet assigned] |

Edit Adverse Event Table Defaults

Help   Definitions

Time Frame for Adverse Event Reporting:
Please provide description of period in which adverse event data were collected (e.g., 1 year, 6 months)

Characters remaining: 255

Additional Description:
Characters remaining: 350

Source Vocabulary Name for Table Default:
Please enter the name and version of the source vocabulary, if any, for adverse event terms. Source Vocabulary will be applied to all adverse event terms entered in the "Serious" and "Other" adverse event tables, unless otherwise specified.
(e.g., SNOMED CT, MedDRA 10.0)

Assessment Type for Table Default:
Assessment type will be applied to all adverse event terms entered in the "Serious" and "Other" adverse event tables, unless otherwise specified.

If systematic, provide explanation of the method in Additional Description.

-- Please Select --

Save   Cancel

| NLM | ID: jftest | Test Test Test Test Test Test | [NCT ID not yet assigned] |

Edit Adverse Event Arms/Groups

+ Add Arm/Group   Help   Definitions

* Arm/Group Title: Drug A | placebo

Arm/Group Description:
Characters remaining: 995 — test
Characters remaining: 995 — test

× Delete   Move ►   × Delete   ◄ Move

| Total for Serious Adverse Events: | 4 Affected Participants out of 12 At Risk | 0 Affected Participants out of 0 At Risk |
| Total for Other (Not Including Serious) Adverse Events: | --- Affected Participants out of --- At Risk | --- Affected Participants out of --- At Risk |

Save   Cancel

| NLM | ID: jftest | Test Test Test Test Test Test | [NCT ID not yet assigned] |

Edit Serious Adverse Event Total

Help   Definitions

Serious Adverse Event(s)	wonderdrug	placebo
* Total Number Affected:	4 participants	0 participants
* Total Number At Risk:	12 participants	0 participants

Tip: The Total Number of Participants at Risk is typically equal to the Number of Participants who Started the first Period in the Participant Flow.   Preview Participant Flow

Save   Validate   Cancel

| NLM | ID: jftest | Test Test Test Test Test Test | [NCT ID not yet assigned] |

Edit Serious Adverse Event Data

Table includes 1 Serious Adverse Event terms

Help   Definitions

		wonderdrug	placebo
	Total Number of Participants Affected/At Risk:	**4/12**	**3/12**
Edit death Blood and lymphati… × Delete	* Affected /At Risk: Number of Events:	4 /12 Edit	3 /12 Edit

+ Add Serious Adverse Event

Save   Validate   Cancel

| NLM | ID: jftest | Test Test Test Test Test | [NCT ID not yet assigned] |

Edit Frequency Threshold for Reporting Other (Not Including Serious) Adverse Events

Help   Definitions

| * Frequency Threshold for Reporting Other Adverse Event: | Enter a number between 0 (no threshold; all events reported) and 5 (only events occurring in greater than 5% of participants in any Arm/Group are reported). |
| | ___ % |

Save   Cancel

| NLM | ID: jftest | Test Test Test Test Test Test | [NCT ID not yet assigned] |

Edit Other (Not Including Serious) Adverse Event Total

Help   Definitions

Other Adverse Event(s)	Drug ABC	placebo
* Total Number Affected:	[____] participants	[____] participants
* Total Number At Risk:	[____] participants	[____] participants

Tip: The Total Number of Participants at Risk is typically equal to the Number of Participants who Started the first Period in the Participant Flow.   Preview Participant Flow

[Save]   [Validate]   [Cancel]

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services

| NLM | ID: jftest | Test Test Test Test Test Test | [NCT ID not yet assigned] |

Edit Limitations and Caveats

Definitions

Overall Limitations and Caveats:

Characters remaining: 250

[   ]

If appropriate, please describe limitations of the trial.
Examples: Early termination leading to small numbers of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data.

[Save]   [Cancel]

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services

NLM   ID: jftest   Test Test Test Test Test Test   [NCT ID not yet assigned]

Edit Certain Agreements

Restrictions on PI after Trial is Completed*

*Other than an agreement solely to comply with applicable provisions of law protecting the privacy of human participants.

Definitions

* Are all PIs Employees of Sponsor?	If all principal investigators are employees of the sponsor, select "Yes". No
Results Disclosure Restriction on PI(s)?	If there is an agreement between the sponsor (or its agent) and any non-employee PI(s) that restricts the PI's rights to discuss or publish trial results after the trial is completed, select "Yes" and select a "Restriction Type." Trial completion is defined as the final date on which data were collected (see Study Completion Date definition). If there are agreements with multiple non-employee PIs and there is a disclosure restriction on at least one PI, select "Yes". Yes
PI Disclosure Restriction Type:	Indicate which type of restriction applies. If there are varying agreements with multiple PIs, choose the type below that represents the most restrictive of the agreements (e.g., the agreement with the greatest embargo time period). ○ None Selected ○ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo. ◉ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo. ○ Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. If the restriction type is "Other disclosure agreement ...", please describe the agreement. Characters remaining: 500

Save   Cancel

NLM   ID: jftest   Test Test Test Test Test Test   [NCT ID not yet assigned]

Edit Results Point of Contact

Definitions

* Name or Official Title: (of Investigator)	adsfads Enter the specific person's name (e.g., Dr. Jane Smith) or a position title (e.g., Director of Clinical Trials).
* Organization Name:	asdfassf
* Phone:	asdfasdf Ext.
* Email:	asdfasdf ⊖ ERROR : An incorrectly formatted Point of Contact Email was entered.

Save   Cancel